Bio-Techne Corporation. (4/24/17). "Press Release: Bio-Techne to Present at the Deutsche Bank 42nd Annual Health Health Care Conference". Minneapolis, MN.

	Region	Boston, MA
	Country	United States (USA)
	Organisation	Bio-Techne Corporation (Nasdaq: TECH)
	Group	Bio-Techne (Group)
	Organisation 2	Deutsche Bank (Group)
	Product	Deutsche Bank Annual Health Care Conference 2017 Boston
	Product 2	laboratory equipment and instruments
	Index term	Bio-Techne–Deutsche Bank: investor conference, 201705 supply service Bio-Techne presents at Deutsche Bank Annual Health Care Conference
	Person	Kummeth, Charles R. (Chuck) (Techne Corp 201304– CEO before Thermo Fisher 201204 Pres Chromatography + MS + 3M Medical)
	Person 2	Clair, David (Bio-Techne 201704 Investor Relations)

Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Deutsche Bank 42nd Annual Health Care conference on Wednesday, May 3, 2017, at 2:10 p.m. EST. The conference will be held at The InterContinental Hotel in Boston.

************

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota. The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,700 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Contact:

David Clair,
Investor Relations
646-277-1266

Record changed: 2023-06-05